The main goal of this study was for researchers to learn more about the safety of
etelcalcetide in children and teenagers with SHPT.
3. Who Was Included in This Study?
Who took part in the study?
This study included 11 children and teenagers with SHPT. Five (5) participants (46%)
were boys and 6 participants (54%) were girls. They ranged in age from 3 to 15 years.
Five (5) participants (46%) were younger than 12 years old. Six (6) participants (54%)
were 12 years or older.
Participants were examined by a study doctor and chosen to be in the study if they:
 Had CKD and SHPT
 Were receiving hemodialysis for more than 30 days before the study started
 Were at least 2 years old, but younger than 18 years old
This study took place at 6 study centers across Belgium, Germany, United Kingdom, and
United States. The numbers of participants in each country are shown below.
devorppA
4. Which Medicines Were Studied?
All participants in this study received 1 dose of etelcalcetide. On day 1 of the study, the
participants were given the etelcalcetide at the end of a hemodialysis treatment. The
dose was 0.035 milligrams per kilogram of weight (mg/kg) and was injected into the
participant’s vein.
3